Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Intramuscular ziprasidone · 1 trial · 1 indication
BPRS is an 18-item clinician rated scale with 11 general symptom items, 5 positive-symptom items, and 2 negative symptom items scored on a 7-point scale (1=not present and 7=extremely severe), with higher score indicating greater severity of symptom. Total possible score range=18 to 126. Change: score at final visit minus score at baseline.
| Arm | Type | Description |
|---|---|---|
| Intramuscular ziprasidone | EXPERIMENTAL | - |
| Intramuscular haloperidol | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Intramuscular ziprasidone mesylate | DRUG | The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days. |
| Intramuscular haloperidol | DRUG | The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days. |
Inclusion Criteria: * Male or female Chinese subjects aged 18-65 years (including 65) at screening. * Subjects meeting the ICD-10 (Classification of Mental and Behavioral Disorders) criteria for schizophrenia (F20.X). * Subjects who are in acute phase of schizophrenia and are appropriate to receive...
Intramuscular ziprasidone is an investigational small molecule being studied for the treatment of agitation in patients with schizophrenia. It is administered by injection and is currently in Phase 3 clinical development. The drug is being developed by Pfizer, Inc. (NYSE: PFE).
Intramuscular ziprasidone is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 3 clinical development for the treatment of agitation in patients with schizophrenia.
Intramuscular ziprasidone is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of agitation in patients with schizophrenia.
Intramuscular ziprasidone has one completed Phase 3 clinical trial, identified as NCT00723606. This was a randomized, open-label, active-controlled, multi-center study conducted in China that evaluated the efficacy and safety of intramuscular ziprasidone in patients with agitation. The trial enrolled 376 participants with schizophrenia.
Intramuscular ziprasidone is a small molecule antipsychotic. As an intramuscular formulation, it is designed to be injected to manage acute agitation in patients with schizophrenia. The specific molecular target of this drug has not been disclosed in the available clinical trial information.